Dianthus Therapeutics, Inc. DNTH
88.81 USD -1.19 (-1.32%)
At closeNov 11, 2026, 4:03 AM EST
89.10 +0.29 +0.33%
Pre-market · Nov 11, 4:03 AM ET
86.92 Day range 90.48
34.29 52-week range 117.88
- YTD
- +115.51%
- 1 year
- +142.58%
News
zacks.com Wall Street Analysts See a 61.23% Upside in Dianthus Therapeutics, Inc. (DNTH): Can the Stock Really Move This High? The mean of analysts' price targets for Dianthus Therapeutics, Inc. (DNTH) points to a 61.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong…
zacks.com Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Beats Revenue Estimates Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to a loss of $0.97 per share a year ago.
globenewswire.com Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 2026 Financial Results Advancing a neuromuscular franchise with claseprubart, a highly potent, investigational classical pathway inhibitor, with best-in-disease potential across generalized Myasthenia Gravis (gMG), Chronic…
benzinga.com This PPL Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Analysts initiated Buy coverage on DRIO ($6), WATT ($15), PPL ($41), DNTH ($113); PYPD rated Outperform with a $10 target.
benzinga.com Roth Capital Initiates Coverage On Dianthus Therapeutics with Buy Rating, Announces Price Target of $113 Roth Capital analyst Adam Walsh initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a Buy rating and announces Price Target of $113.
benzinga.com HC Wainwright & Co. Reiterates Buy on Dianthus Therapeutics, Maintains $158 Price Target HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and maintains $158 price target.